Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genentech (NYSE:DNA) formerly known as (NYSE:GNE) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (227)	2/2/2009 4:25:37 PM
From: kenhott	Respond to of 250

I looked thru the Dealbook article and I think they are making the same sort of mistakes trying to understand the agreement between Roche and DNA. Of course it can always be me who are making the misread. If you are going to trade the stocks, you may want to read the SEC filing yourself to get a complete understanding of the agreement. For others, no need to read this War and No Peace and risk falling to sleep in the middle of the day. <I wonder 1) if DNA already has an idea of how the Avastin results will turn out, and 2) if Roche can legally buy shares in the open market at this point.> Roche and DNA may think they have an idea on what is going on with the trial, but that is as we know far from a sure thing. Roche can buy whatever they want as long as they stand by the agreement. Be careful out there.